The Personalis Mission
To transform the development of next-generation cancer therapies by providing more comprehensive molecular data about each patient’s tumor.

Elucidating Complex Biology in the Immuno-Oncology Era

Personalis is focused on providing the most extensive molecular view of a patient’s tumor and characterizing its interplay with the immune system. By partnering with some of the world’s largest and most innovative biopharmaceutical companies, Personalis aids in the development of safer, more effective precision cancer therapies and personalized medicines.
The success of checkpoint blockade has demonstrated that when tumor-imposed brakes are taken off the immune system, the subsequent immune response can effectively treat the disease. However, only a small minority of cancer patients have so far benefitted from this therapeutic revolution. Effectively predicting response to immunotherapies — and developing new ones — requires a more comprehensive approach to tumor immunogenomics; enabling the identification of composite biomarkers of clinical utility. This is why we’ve developed the ImmunoID NeXT Platform™.

ImmunoID NeXT™

The Universal Cancer Immunogenomics Platform

ImmunoID NeXT is the first platform to enable the comprehensive analysis of both a tumor and its microenvironment from a single sample. Providing genomic information for all ~20,000 genes, ImmunoID NeXT consolidates multiple oncology biomarker assays into one – maximizing the biological insights gained from a single sample. When specimens are limited, researchers must make difficult decisions regarding which biomarkers to analyze.
With ImmunoID NeXT, this problem is a thing of the past.

A Single Platform. A Single Sample. Multiple Biomarkers.

Predictive & Prognostic
Biomarker Discovery

ImmunoID NeXT provides a multidimensional view of the tumor and the TME, empowering our partners to extract the most information from the least amount of sample.

Personalized Cancer
Therapeutic Development

Personalis is the premier partner for the identification of neoantigens at the preclinical, clinical trial, and post-approval stages of the drug development process.

Ready to streamline your precision oncology 
translational and clinical research programs?

Join Us!
  • AACR Tumor Immunology and Immunotherapy Conference USA, Boston, MA | November 17-20
  • NeoAG Summit USA, Boston, MA | November 21-22
  • ESMO Immuno-Oncology Congress, Geneva, Switzerland | December 11-14